CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
Abstract Background Chronic myeloid leukemia stem cells (CML-LSCs), which exhibit resistance to tyrosine kinase inhibitors (TKIs), are the leading cause of treatment failure and recurrence in chronic myeloid leukemia (CML). This highlights the urgent need for novel therapies aimed at eliminating the...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-025-00608-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850198061459963904 |
|---|---|
| author | Jiang Guoyun Qin Yuefeng Huang Zhenglan Yuan Zuowei Zhou Hongyan Yuan Ying Feng Wenli |
| author_facet | Jiang Guoyun Qin Yuefeng Huang Zhenglan Yuan Zuowei Zhou Hongyan Yuan Ying Feng Wenli |
| author_sort | Jiang Guoyun |
| collection | DOAJ |
| description | Abstract Background Chronic myeloid leukemia stem cells (CML-LSCs), which exhibit resistance to tyrosine kinase inhibitors (TKIs), are the leading cause of treatment failure and recurrence in chronic myeloid leukemia (CML). This highlights the urgent need for novel therapies aimed at eliminating these CML-LSCs. Chimeric antigen receptor macrophages (CAR-M) not only perform phagocytosis on target cells but also function as antigen-presenting cells, thereby activating the anti-tumor immune response.CD26 (dipeptidyl peptidase 4, DPP IV) is abundantly expressed in CML-LSCs and functions as a tumor-specific antigen (TSA) in CAR-M treatment. The purpose of this study is to evaluate CAR-M’s efficacy in targeting CD26-positive CML cells and to develop a novel strategy for CML treatment. Methods CD26 CAR-M was constructed using mouse-derived macrophage Raw264.7 cells. CD26 was overexpressed in CML cell lines BP210 and BP210-T315I. The targeting phagocytosis of CAR-M was verified using confocal microscopy and flow cytometry. X-ray was used to eliminate the tumorigenicity of CAR-M, and the safety of CAR-M was verified through CCK-8, clone formation assays, and animal experiments. To assess the anti-leukemia ability of CAR-M in the CML mouse model, the survival, peripheral blood white blood cell counts, and CML cell infiltration in the liver, spleen, and bone marrow (BM) were measured. Additionally, CD26 CAR-THP1 was constructed, and its phagocytic ability against CD26-positive cells NCI-H2452 was confirmed by confocal microscopy. Results We successfully constructed CD26 CAR-M and validated its targeted phagocytosis of CD26-positive CML cells both in vitro and in vivo. The data indicate that CAR-M has higher phagocytic efficiency in CD26-positive CML cells than in CD26-negative cells. CAR-M-treated CML mice demonstrated extended survival and reduced CML invasion. In addition, CAR-THP1 demonstrated targeted phagocytosis of NCI-H2452 cells that normally express CD26. Conclusion This study demonstrates that CD26 CAR-M effectively targets and phagocytizes CD26-positive CML cells, implying that targeting CD26 with CAR-M could be a viable method for eradicating CML-LSCs. Furthermore, our discoveries illuminate the potential application of CAR-M in treating hematological malignancies. |
| format | Article |
| id | doaj-art-410ff9d6689d4121978e68bf6f6fa316 |
| institution | OA Journals |
| issn | 2162-3619 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj-art-410ff9d6689d4121978e68bf6f6fa3162025-08-20T02:12:58ZengBMCExperimental Hematology & Oncology2162-36192025-02-0114111310.1186/s40164-025-00608-9CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cellsJiang Guoyun0Qin Yuefeng1Huang Zhenglan2Yuan Zuowei3Zhou Hongyan4Yuan Ying5Feng Wenli6Department of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical UniversityDepartment of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical UniversityDepartment of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical UniversityDepartment of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical UniversityDepartment of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical UniversityDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical UniversityDepartment of Clinical Hematology, School of Laboratory Medicine, Chongqing Medical UniversityAbstract Background Chronic myeloid leukemia stem cells (CML-LSCs), which exhibit resistance to tyrosine kinase inhibitors (TKIs), are the leading cause of treatment failure and recurrence in chronic myeloid leukemia (CML). This highlights the urgent need for novel therapies aimed at eliminating these CML-LSCs. Chimeric antigen receptor macrophages (CAR-M) not only perform phagocytosis on target cells but also function as antigen-presenting cells, thereby activating the anti-tumor immune response.CD26 (dipeptidyl peptidase 4, DPP IV) is abundantly expressed in CML-LSCs and functions as a tumor-specific antigen (TSA) in CAR-M treatment. The purpose of this study is to evaluate CAR-M’s efficacy in targeting CD26-positive CML cells and to develop a novel strategy for CML treatment. Methods CD26 CAR-M was constructed using mouse-derived macrophage Raw264.7 cells. CD26 was overexpressed in CML cell lines BP210 and BP210-T315I. The targeting phagocytosis of CAR-M was verified using confocal microscopy and flow cytometry. X-ray was used to eliminate the tumorigenicity of CAR-M, and the safety of CAR-M was verified through CCK-8, clone formation assays, and animal experiments. To assess the anti-leukemia ability of CAR-M in the CML mouse model, the survival, peripheral blood white blood cell counts, and CML cell infiltration in the liver, spleen, and bone marrow (BM) were measured. Additionally, CD26 CAR-THP1 was constructed, and its phagocytic ability against CD26-positive cells NCI-H2452 was confirmed by confocal microscopy. Results We successfully constructed CD26 CAR-M and validated its targeted phagocytosis of CD26-positive CML cells both in vitro and in vivo. The data indicate that CAR-M has higher phagocytic efficiency in CD26-positive CML cells than in CD26-negative cells. CAR-M-treated CML mice demonstrated extended survival and reduced CML invasion. In addition, CAR-THP1 demonstrated targeted phagocytosis of NCI-H2452 cells that normally express CD26. Conclusion This study demonstrates that CD26 CAR-M effectively targets and phagocytizes CD26-positive CML cells, implying that targeting CD26 with CAR-M could be a viable method for eradicating CML-LSCs. Furthermore, our discoveries illuminate the potential application of CAR-M in treating hematological malignancies.https://doi.org/10.1186/s40164-025-00608-9Chronic myeloid leukemiaChimeric antigen receptorMacrophageCD26 |
| spellingShingle | Jiang Guoyun Qin Yuefeng Huang Zhenglan Yuan Zuowei Zhou Hongyan Yuan Ying Feng Wenli CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells Experimental Hematology & Oncology Chronic myeloid leukemia Chimeric antigen receptor Macrophage CD26 |
| title | CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells |
| title_full | CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells |
| title_fullStr | CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells |
| title_full_unstemmed | CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells |
| title_short | CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells |
| title_sort | car macrophages targets cd26 to eliminate chronic myeloid leukemia stem cells |
| topic | Chronic myeloid leukemia Chimeric antigen receptor Macrophage CD26 |
| url | https://doi.org/10.1186/s40164-025-00608-9 |
| work_keys_str_mv | AT jiangguoyun carmacrophagestargetscd26toeliminatechronicmyeloidleukemiastemcells AT qinyuefeng carmacrophagestargetscd26toeliminatechronicmyeloidleukemiastemcells AT huangzhenglan carmacrophagestargetscd26toeliminatechronicmyeloidleukemiastemcells AT yuanzuowei carmacrophagestargetscd26toeliminatechronicmyeloidleukemiastemcells AT zhouhongyan carmacrophagestargetscd26toeliminatechronicmyeloidleukemiastemcells AT yuanying carmacrophagestargetscd26toeliminatechronicmyeloidleukemiastemcells AT fengwenli carmacrophagestargetscd26toeliminatechronicmyeloidleukemiastemcells |